El Kik Antoine, Vander Kuylen Maarten, Bailly Benjamin, Fallas Jennifer, Bondue Benjamin
Department of Pneumology, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Department of Thoracic Surgery, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Respir Med Case Rep. 2024 Aug 5;51:102090. doi: 10.1016/j.rmcr.2024.102090. eCollection 2024.
Although pulmonary complications are frequent in patients suffering from hematological diseases, secondary pulmonary alveolar proteinosis is a very rare complication of myelofibrosis. We describe the case of a 65-year-old male patient treated by Ruxolitinib for myelofibrosis who developed a secondary pulmonary alveolar proteinosis complicated by a infection. We believe that this respiratory complication might be related to the myelofibrosis and to the initiation of the Ruxolitinib according to its temporal relationship. Pulmonologists should be aware that respiratory symptoms in myelofibrosis patients taking Ruxolitinib may be related to pulmonary alveolar proteinosis.
尽管肺部并发症在血液病患者中很常见，但继发性肺泡蛋白沉积症是骨髓纤维化非常罕见的并发症。我们描述了一例65岁男性患者，他因骨髓纤维化接受芦可替尼治疗，并发继发性肺泡蛋白沉积症并伴有感染。根据其时间关系，我们认为这种呼吸系统并发症可能与骨髓纤维化以及芦可替尼的使用有关。肺科医生应该意识到，服用芦可替尼的骨髓纤维化患者出现的呼吸道症状可能与肺泡蛋白沉积症有关。
